Lineage Cell Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
AMEX
Lineage Cell Therapeutics reported a significant net loss in Q3 2025, driven by non-cash charges, while advancing its OpRegen and OPC1 clinical programs and securing a new collaboration for ReSonance.
AMEX
Lineage Cell Therapeutics reported a significant net loss for Q2 2025, primarily driven by a $14.8 million intangible asset impairment related to the abandoned VAC platform, despite positive clinical updates for OpRegen and OPC1.
AMEX
Lineage Cell Therapeutics announces its financial results for the first quarter of 2025, showcasing advancements in its allogeneic cell therapy programs for neurological and ophthalmic conditions.
AMEX
10-Q: Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Lineage Cell Therapeutics reported its financial results for the third quarter of 2024, highlighting progress in its cell therapy programs and ongoing collaborations.
AMEX
10-Q: Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results, Provides Business Update
Lineage Cell Therapeutics reported a net loss of $12.3 million for the first half of 2024, with a decrease in collaboration revenue offset by reduced research and development expenses.
AMEX
10-Q: Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Lineage Cell Therapeutics reported a net loss of $6.5 million for the first quarter of 2024, with a decrease in collaboration revenue offset by a recent capital raise.